Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
chronic kidney disease 3 nephrologydiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
chronic kidney disease 411 (B.E.Y.)Publication date (epub): 8/2017Publication date (collection): 8/2017AbstractThe incidence of chronic kidney disease (CKD) is increasing worldwide, with more than 26 million people suffering from CKD in the United States
chronic kidney disease 1800 risk in this patient group.1. IntroductionMore than 26 million people in the United States suffer from chronic kidney disease (CKD) with thousands of new cases diagnosed each year [[1]]. CKD has poor prognosis and health outcomes
chronic kidney disease 29802 group IV. With decreasing eGFR, there is a significant and progressive increase in resting MSNA in chronic kidney disease (CKD) patients. * p < 0.05 significant difference between quartiles. (From Grassi et al. [[13]] with

You must be authorized to submit a review.